Drug-response analysis of the patient-derived xenograft (PDX) platform (DRAP) following GET revealed delayed tumor growth in both GET-treated groups compared with the control (Ctrl) group, but this difference did not reach statistical significance ( Figure 1 A).
← all excerpts
Transcriptomic analysis of the immune response to <i>in vivo</i> gene electrotransfer in colorectal cancer.
1
—
—